Preliminary knockdown studies using flow cytometry to evaluate the effects of anti-TNF-α siRNA delivery confirmed the safety of the FAuNCs in non-cancer cells and showed selective inhibition of MDA-MB-231 cell growth. This evidence concerns the gene TNF and cancer.